Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...138139140141142143144145146147148...401402»
  • ||||||||||  Journal:  Assessment and Management of Appetite Loss in Older Adults: An ICFSR Task Force Report. (Pubmed Central) -  Jan 12, 2023   
    As research on biomarkers of appetite loss progresses, assessment tools will soon be used jointly with biomarkers for more accurate diagnosis and prognosis. In addition, efforts to foster the development of drugs with a favorable risk/benefit ratio to combat poor appetite should be strengthened.
  • ||||||||||  Journal:  Low Intake of Choline Is Associated with Diminished Strength and Lean Mass Gains in Older Adults. (Pubmed Central) -  Jan 12, 2023   
    In addition, efforts to foster the development of drugs with a favorable risk/benefit ratio to combat poor appetite should be strengthened. These data suggest that this population of older adults does not consume adequate choline and lower choline intake is negatively and independently associated with muscle responses to RET.
  • ||||||||||  Acomplia (rimonabant) / Sanofi
    Preclinical, Journal:  Inhibition of the endocannabinoid system reverses obese phenotype in aged mice and partly restores skeletal muscle function. (Pubmed Central) -  Jan 12, 2023   
    The aims of this study were to evaluate the effect of an inhibition of the ECS by rimonabant (RIM) on the metabolic alterations induced by a high-fat high-sucrose diet, and on skeletal muscle mass/function in aged mice...Lipolysis and b-oxidation genes were up-regulated in the liver as well as genes involved in adipose tissue browning. These results demonstrate that inhibition of the ECS induces metabolic changes in liver and adipose tissue associated with a reversion of the obese phenotype, and that RIM is able to improve motor coordination and muscle strength in aged mice, without affecting skeletal muscle mass.
  • ||||||||||  Humalog pen (insulin lispro) / Eli Lilly
    Trial completion date, Trial primary completion date:  Effects of Insulin on Hypotension and Sarcopenia (clinicaltrials.gov) -  Jan 12, 2023   
    P=N/A,  N=0, Withdrawn, 
    In order to offset the poor prognosis associated with sarcopenia particularly in metastatic esophageal adenocarcinoma patients, future research should focus on possible countermeasures. Trial completion date: Oct 2019 --> Jan 2023 | Trial primary completion date: Oct 2019 --> Jan 2023
  • ||||||||||  Journal:  Associations of swallowing-related muscle quantity and quality with sarcopenic parameters. (Pubmed Central) -  Jan 11, 2023   
    A multidisciplinary approach to preoperative sarcopenia, taking exercise and nutrition into account, is recommended. These findings may facilitate the early detection of aging-related deterioration in swallowing-related musculature through the diagnostic process of sarcopenia and increase our understanding of muscle physiology.
  • ||||||||||  Review, Journal:  Imaging of muscle and adipose tissue in the spine: A narrative review. (Pubmed Central) -  Jan 11, 2023   
    Currently, there is no summary of studies on fat and muscle in the spinal region. Given this, within the context of recent research trends, this article provides a synthesis of research on adipose and muscle tissue in the spine, discusses advances in the study of the imaging manifestations of these structures in spinal disorders, and expands the perspectives.
  • ||||||||||  Review, Journal:  The critical role of gut microbiota dysbiosis in skeletal muscle wasting: a systematic review. (Pubmed Central) -  Jan 11, 2023   
    Given this, within the context of recent research trends, this article provides a synthesis of research on adipose and muscle tissue in the spine, discusses advances in the study of the imaging manifestations of these structures in spinal disorders, and expands the perspectives. This systematic review presents associations between the gut microbiota alterations and skeletal muscle wasting as a consequence of various pathologies, including aging sarcopenia, renal failure, and cancer cachexia in both human and animal studies.
  • ||||||||||  Journal, Machine learning:  Machine Learning Model in Predicting Sarcopenia in Crohn's Disease Based on Simple Clinical and Anthropometric Measures. (Pubmed Central) -  Jan 9, 2023   
    A comprehensive comparison showed that LightGBM was the most ideal diagnostic model, with an AUC of 0.933, AUCPR of 0.970, sensitivity of 72.7%, and specificity of 87.0%. The LightGBM model may facilitate a population management strategy with early identification of sarcopenia in Crohn's disease, while providing guidance for nutritional support and an alternative surveillance modality for long-term patient follow-up.
  • ||||||||||  Review, Journal, Metastases:  Prognostic Impact of Sarcopenia in Patients with Advanced Prostate Carcinoma: A Systematic Review. (Pubmed Central) -  Jan 9, 2023   
    Patient summary: The literature was reviewed to determine whether the loss of muscle mass (sarcopenia) affects the survival in patients with advanced PCa. Patients with advanced PCa and sarcopenia were found to have a shorter progression-free survival (the length of time during and after treatment of a cancer that the patient lives with the disease but it does not get worse), but sarcopenia did not have much influence on the overall survival and cancer-specific survival (the length of time from either the date of diagnosis or the start of treatment to the date of death due to the cancer).
  • ||||||||||  Review, Journal:  Frailty, sarcopenia and COVID-19 in geriatric patients (literature review). (Pubmed Central) -  Jan 9, 2023   
    The current COVID-19 pandemic, accompanied by a significant increase in mortality among the elderly and senile, makes it necessary to investigate the reasons underlying the increased vulnerability of geriatric patients to this disease. This review of the literature is devoted to this problem.
  • ||||||||||  dexamethasone injection / Generic mfg.
    Journal:  Is dexamethasone-induced muscle atrophy an alternative model for naturally aged sarcopenia model? (Pubmed Central) -  Jan 7, 2023   
    21-month-old mice were used as naturally aged primary sarcopenia mice and 3-month-old mice received daily intraperitoneal injection of dexamethasone (20 mg/ kg body weight) for 10 days were used as secondary sarcopenia model...Using animal models for the preclinical study could predict the safety and efficacy of the treatments. This study compared the typical age-related sarcopenia mice model and dexamethasone-induced secondary sarcopenia mice to provide evidence of the pathological and functional changes in the mice models.